

Current research opportunities in Nottingham for people with dementia

For information for Centre for Dementia PPI participants, referred to at the 13 November 2014 consultation Event.

Please note: To take part in the studies detailed below, people need to be referred by a doctor in the Trust or by their own GP.

There are two clinical trials currently recruiting patients. One is for people with early Alzheimer's disease, called the MADE study. The other is for people with vascular dementia (of a specific type) at an early stage, called the AFFECT study.

A further study, not a treatment study, the IDEAL study, is looking at people with early dementia (of any sort) and, where possible, their carer. It holds a series of interviews with them over three years to find out what helps them to 'live well' with dementia and/or what tends to cause problems for them, aiming to see how things can be helped to work better in the future. IDEAL stands for Improving the experience of Dementia and Enhancing Active Life.

All three of these studies are seeking to recruit from the 'Memory Clinics'/Memory Assessment Services (MAS) of the Nottinghamshire Healthcare Trust, which means that when people are recruited they will at that time be patients of the Trust. People who are already patients of the Trust can ask their clinicians to consider referring them on to the studies. People who are not patients would have to ask their General Practitioners (GP's) kindly to refer them to the 'Memory Clinic' for their area in the Trust (or, just back to the Trust, if they have already been to the 'Memory Clinic') for this recruitment to be considered there. People are not able to enter the studies directly outside of that route.

Some further detail about the MADE study is given below. It is the **Minocycline in Alzheimer's Disease Efficacy** study and participants will be given either minocycline (already licensed as a tetracycline antibiotic) or a placebo (a dummy inactive pill) for 2 years, and followed up to assess their progress. The study wants people diagnosed with Alzheimer's disease in the early stages, who score 23 or more on the Mini Mental State Examination (the MMSE), on which people who have no cognitive problems generally score 29 or 30.

Some further detail about the AFFECT study is given below. It is the **Amlodipine For the treatment of subcortical ischaemic vascular dementia** study and participants will be given either amlodipine (already licensed as a treatment given to people with raised blood pressure) or a placebo (a dummy inactive pill) for 1 year, and followed up to assess their progress. The study wants people diagnosed with vascular dementia in the early stages, who score 20-26 on the Mini Mental State Examination (the MMSE), on which people who have no cognitive problems generally score 29 or 30.

Please note: To take part in these studies, people need to be referred by a doctor in the Trust or by their own GP.